Rhythm Pharmaceuticals (RYTM) Tops Q2 EPS by 8c
Tweet
Share
E-mail
Get Alerts RYTM Hot Sheet
Join SI Premium – FREE
Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q2 EPS of ($0.73), $0.08 better than the analyst estimate of ($0.81). Revenue for the quarter came in at $71.26 million versus the consensus estimate of $67.53 million.
For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McDonald’s tops EPS estimates, but revenue falls short
- TPG (TPG) Tops Q2 EPS by 22c
- Grainger (GWW) Tops Q2 EPS by 73c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
